1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,300 | 1,360 | 10:41 | |
| 1,300 | 1,360 | 10:29 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| Mi | Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily | 386 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, reports that a... ► Artikel lesen | |
| Mo | Noble Capital startet Coverage für NanoViricides mit "Outperform" | 1 | Investing.com Deutsch | ||
| Mo | Noble Capital initiates NanoViricides stock with Outperform rating | 3 | Investing.com | ||
| Mo | As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo | 321 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it... ► Artikel lesen | |
| 29.06. | NanoViricides: US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher | 638 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 29, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of... ► Artikel lesen | |
| 22.06. | NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo | 901 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 22, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today announced that it has shipped the NV-387 Oral Gummies Drug Product for a Phase II Clinical... ► Artikel lesen | |
| 15.06. | As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo | 1.000 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides... ► Artikel lesen | |
| 08.06. | As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies | 742 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides... ► Artikel lesen | |
| 26.05. | In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides | 781 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 26, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, compares potential... ► Artikel lesen | |
| 20.05. | NANOVIRICIDES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.05. | NanoViricides Announces Closing of ~$2 Million Registered Direct Offering | 763 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 18.05. | Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides | 831 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the... ► Artikel lesen | |
| 15.05. | NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering | 582 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 15.05. | NanoViricides GAAP EPS of -$0.09 | 3 | Seeking Alpha | ||
| 15.05. | NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II | 546 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending March... ► Artikel lesen | |
| 11.05. | Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides | 717 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 11, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the... ► Artikel lesen | |
| 06.05. | D.Boral Capital: NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference | 803 | Newsfile | Shelton, Connecticut--(Newsfile Corp. - May 6, 2026) - NanoViricides, Inc. (NYSE American: NNVC), today announced its participation in the D. Boral Capital Global Conference, taking place May 7... ► Artikel lesen | |
| 04.05. | NanoViricides: NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA | 600 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 4, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of... ► Artikel lesen | |
| 21.04. | Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides | 672 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 07.04. | Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides | 883 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of... ► Artikel lesen |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 18,900 | +2,05 % | BioNTech, Merck oder Formycon? Das ist unser Geheimtipp! | Die Aktien von BioNTech, Merck und Formycon präsentieren sich derzeit mit einer unterschiedlichen Kursdynamik. Während BioNTech nach einer Erholungsbewegung wieder verstärkt in den Fokus wachstumsorientierter... ► Artikel lesen | |
| NVE | 80,50 | +0,62 % | Dividendenbekanntmachungen (18.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A2A SPA IT0001233417 - 0,104 EUR AIR LIQUIDE SA FR0000120073 - 3,7 EUR ALCOA CORPORATION CDIS AU0000339426 0,1 USD 0,086 EUR ALLISON... ► Artikel lesen | |
| SMOLTEK NANOTECH | 0,177 | -5,09 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.06.2026 | Das Instrument G85 CA35958L1013 FUERTE METALS CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 09.06.2026 und ex Kapitalmassnahme am 10.06.2026 The instrument G85 CA35958L1013 FUERTE METALS CORP.... ► Artikel lesen | |
| KOPIN | 3,390 | -1,54 % | Fabric.AI (Nasdaq: FABC) Stockholders Ratify Kopin Strategic Partnership to Develop Neural I/o MicroLED Optical Interconnect Technology for Next Generation AI Data Centers | NEW YORK, NY, June 24, 2026 (GLOBE NEWSWIRE) -- Fabric.AI, Inc. (Nasdaq: FABC) ("Fabric.AI" or the "Company"), a fabless semiconductor company developing MicroLED-based optical interconnects for AI... ► Artikel lesen | |
| GAUZY | 0,407 | -5,32 % | Gauzy Ltd. Announces Receipt of Nasdaq Notice Regarding Delayed Filing of Annual Report on Form 20-F | TEL AVIV, Israel, May 26, 2026 (GLOBE NEWSWIRE) -- Gauzy Ltd. (NASDAQ: GAUZ) ("Gauzy" or the "Company"), a global leader in vision and light control technologies, today announced that on May 19, 2026... ► Artikel lesen | |
| ONTO INNOVATION | 262,50 | +2,98 % | $1000 Invested In Onto Innovation 5 Years Ago Would Be Worth This Much Today | ||
| SOLESENCE | 0,700 | 0,00 % | Solésence, Inc.: Solésence Reports Fourth Quarter and Full-Year 2025 Financial Results | Full Year 2025 record revenue of $62.1 million ROMEOVILLE, Ill., March 31, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty... ► Artikel lesen | |
| OBDUCAT | 0,051 | +2,00 % | NGM MARKET NOTICE: #26-16 Information regarding the last day of trading in paid subscribed units and the first day of trading in warrants issued by Obducat AB | ||
| VEECO INSTRUMENTS | 47,810 | +0,99 % | Veeco Instruments Inc.: Veeco Announces $250 Million+ in Equipment Orders for Manufacturing Indium Phosphide Lasers | High-volume orders from multiple customers for its Spector, Lumina and Wet Processing Systems to drive strong growth. PLAINVIEW, N.Y., May 05, 2026 (GLOBE NEWSWIRE) -- Veeco Instruments Inc. (NASDAQ:... ► Artikel lesen | |
| LAMPETIA | 0,140 | 0,00 % | EQS-Adhoc: Lampetia AG: Lampetia hebt Gewinnprognose für das laufende Geschäftsjahr deutlich an | EQS-Ad-hoc: Lampetia AG / Schlagwort(e): Prognose / Gesamtjahr
Lampetia AG hebt Gewinnprognose für das laufende Geschäftsjahr deutlich an
01.07.2026 / 19:30 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| ACACIA RESEARCH | 3,820 | +0,53 % | ACACIA RESEARCH CORP - 8-K, Current Report | ||
| ADVANCE ZINCTEK | 0,426 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 16.02.2026 | Das Instrument OYS US68162K1060 OLYMPIC STEEL EQUITY wird cum Kapitalmassnahme gehandelt am 16.02.2026 und ex Kapitalmassnahme am 17.02.2026 The instrument OYS US68162K1060 OLYMPIC STEEL EQUITY is traded... ► Artikel lesen | |
| RIBER | 10,380 | +7,01 % | RIBER receives a new order from 3SP Technologies for a production platform | RIBER receives a new order from 3SP Technologies for a production platform Bezons (France), July 9, 2026 - 8:00 am (CET) - RIBER, a global market leader in molecular beam epitaxy (MBE) equipment for... ► Artikel lesen | |
| DOTZ NANO | 0,011 | +6,06 % | XFRA 57N: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| GOMSPACE | 1,324 | -2,29 % | GOMSPACE GROUP AB: GomSpace contributes to ESA's RAMSES mission with 2 MEUR (22.2 MSEK) contract to support Apophis asteroid exploration |
NANOVIRICIDES INC gehört der Branche Nanotechnologie an. Die relative Kursveränderung beträgt aktuell +1,48 % bei einem Aktienkurs von 1,370 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.